Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
Breast Cancer, Colorectal Cancer, Lung Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring male breast cancer, recurrent breast cancer, recurrent colon cancer, recurrent non-small cell lung cancer, recurrent pancreatic cancer, recurrent rectal cancer, stage III colon cancer, stage III pancreatic cancer, stage III rectal cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer, stage IV colon cancer, stage IV non-small cell lung cancer, stage IV rectal cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV pancreatic cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed metastatic, recurrent, or unresectable locally advanced solid tumor, including one of the following: Breast or colorectal cancer that has failed first-line chemotherapy Non-small cell lung cancer Pancreatic Cancer No CNS metastases Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age 18 and over Sex Male or female Menopausal status Not specified Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 2.0 mg/dL No clinically significant hepatic dysfunction Renal Creatinine no greater than 2.5 mg/dL No clinically significant renal dysfunction Other Not pregnant or nursing Negative pregnancy test HIV negative No clinically significant unrelated illness (e.g., serious infection or organ dysfunction) that would preclude study tolerance PRIOR CONCURRENT THERAPY: Biologic therapy No prior mistletoe Chemotherapy See Disease Characteristics No prior gemcitabine More than 30 days since prior chemotherapy and recovered Endocrine therapy More than 30 days since prior glucocorticosteroid therapy Radiotherapy Recovered from prior radiotherapy Surgery Recovered from prior surgery Other At least 30 days since prior investigational agents No other concurrent investigational agents
Sites / Locations
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office